Research progress in the use of drugs for breast cancer targeted therapy

In recent years, many significant advances have been made on molecular target therapy to aim directly at epidermal growth factor receptors and vascular endothelial growth factor in breast cancers. Clinical studies of such agents as trastuzumab, lapatinib, erlotinib and bevacituzumab have been widely conducted. This paper will review the recent research progress related to targeted therapy.